Psilocybin study for chemo neuropathy
Analysis based on 14 articles · First reported Sep 03, 2026 · Last updated Sep 06, 2026
The findings could accelerate development of psilocybin-based therapies for chemotherapy-induced peripheral neuropathy, a condition affecting millions of cancer patients. This may boost investment in psychedelic medicine companies and related biotech firms, while also influencing regulatory pathways for psychedelic treatments.
A study published in the journal Science on September 3, 2026, found that psilocybin, the hallucinogenic compound in magic mushrooms, may prevent peripheral neuropathy caused by chemotherapy. The research, conducted by scientists at the MD Anderson Cancer Center, involved tests on rats and human tissues. It showed that psilocybin protects nerve cells and preserves mitochondrial transport, preventing the painful nerve damage that affects about three-quarters of chemotherapy patients. Two doses before chemo prevented hypersensitivity in rodents for up to six treatment rounds without compromising the immune system or anti-cancer effects. The nerve-protective effect appears independent of hallucinogenic properties, as a non-hallucinogenic analogue showed similar results. The MD Anderson Cancer Center plans to launch clinical trials later this year. Researchers caution against self-medication, as psilocybin can amplify stress and anxiety in unsupervised cancer patients. The study was supported by a boom in psychedelic research and an April executive order by President Donald Trump to expedite research and regulatory reviews.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard